[2]Hamilton E, Loibl S, Niikura N, et al. A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2e early breast cancer (BC)...
[2] Bartsch R, Harbeck N, Wrobel D, et al. Interim analysis (n=200) from ELEANOR: A multi-national, prospective,non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adju...
[2] Bartsch R, Harbeck N, Wrobel D, et al. Interim analysis (n=200) from ELEANOR: A multi-national, prospective,non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical rout. 2023 SABCS. Poster P2-01-01. [3]...
苏州2023年10月23日/美通社/ -- 2023年欧洲肿瘤内科学会(ESMO)年会于中欧夏令时间2023年10月20日至10月24日在西班牙马德里盛大召开。本届ESMO年会上,开拓药业以壁报(Poster)形式公布了普克鲁胺联合内分泌药物(ETs)治疗转移性乳腺癌(mBC)在中国的Ic期临床研究最新成果。该项由北京大学肿瘤医院李惠平教授担任主要研究...
Dxcover Limited today announced that it has been awarded first prize for its poster focused on the detection of early-stage tumors across multiple cancers at the European Society for Medical Oncology (ESMO) Congress 2023 in the Innovative Di...
◆ 会议时间:2023年5月11日至13日 ◆ 会议地点:德国 柏林(Berlin, Germany) ◆ 下次会议:2024年欧洲肿瘤内科学会ESMO乳腺癌年会/大会(ESMO Breast Cancer 2024) ◆ 会议简介: 2023年欧洲肿瘤内科学会(ESMO)乳腺癌大会(年会)将于2023年5月11日至13日在德国柏林举行。ESMO乳腺癌年会是在欧洲举行的一个多学科全...
Abstract #: 1070 | Poster Bd #: 291 Session Title: Breast Cancer – Metastatic Session Date and Time:June 4, 2023;8:00AM CDT, Hall A Presentation Type: Poster About the EMERALD Phase 3 Study (NCT03778931) The EMERALD Phase 3 trial is a r...
Please note that all abstracts must relate to advanced (not early) breast cancer in order to be considered. Abstracts will be assessed for presentation at the Conference, either oral or poster, or for publication in the ABC7 Abstract Book, supplement ofThe Breast. ...
2023年欧洲肿瘤内科学会(ESMO)大会将于当地时间2023年10月20日-10月24日在西班牙马德里盛大召开。信达生物旗下多款创新产品的临床研究入选此次大会,其中1项研究入选迷你口头报告(MiniOral,MO),16项研究入选壁报展示(Poster,P)。同时礼来制药发布了2项塞普替尼的临床研究入选主席会议。信达生物负责该产品在中国的商业...
Session Title: Breast Cancer - MetastaticSession Date and Time: June 4, 2023; 8:00AM CDT, Hall APresentation Type: Poster About the EMERALD Phase 3 Study (NCT03778931)The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or ...